Gentamicin- and clindamycin-resistant Staphylococcus aureus

Abstract

From 1975 through 1978 isolates from 21 of 230 (9%) Staphylococcus aureus bacteremias were resistant to gentamicin and clindamycin. Gentamicin- and clindamycin-resistant S aureus (GCRS) accounted for 23% of all S aureus isolates from 1977 compared with 2 to 6% in the two years immediately preceding, and the year following 1977. When compared with patients with gentamicin- and clindamycin-sensitive S 3£y/-eus(GCSS)from 1977, GCRS were more often isolated from patients who acquired their infections in the hospital, particularly in the intensive care unit. A significant association existed between prior or concurrent therapy with gentamicin and/or clindamycin and the isolation of GCRS. Infection with GCRS was associated with a 73% mortality rate versus 28% with GCSS. GCRS were susceptible to oxacillin, cephalothin, tetracycline, and vancomycin. GCRS were resistant to kanamycin and tobramycin but were susceptible to amikacin (median MIC of GCRS, 4.0 μg/ml). Multiple bacteriophage types of S aureus were involved, and resistance appeared to be plasmid-mediated. A survey of antibiotic usage showed that in comparison to January 1977, amikacin usage increased and gentamicin usage decreased in March 1979. Because of the popularity of the combination of clindamycin and gentamicin for therapy of life-threatening infections, clinicians should be aware of potential gentamicin- and clindamycin-resistance in S aureus.